• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Astellas Pharma Inc (OP: ALPMY )

    9.995 -0.025 (-0.25%)
    Streaming Delayed Price Updated: 3:50 PM EDT, Jul 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 114,848
    Open 9.910
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 10.02
    Today's Range 9.900 - 10.01
    52wk Range 9.150 - 15.90
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
    MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
    Via Talk Markets
    Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
    Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... 
    Via Talk Markets

    Performance

    YTD
    -15.51%
    -15.51%
    1 Month
    -0.55%
    -0.55%
    3 Month
    -4.99%
    -4.99%
    6 Month
    -18.61%
    -18.61%
    1 Year
    -30.59%
    -30.59%

    More News

    Read More
    Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
    Via Benzinga
    How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks
    Via Investor's Business Daily
    Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study
    Via Benzinga
    Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years
    Via The Motley Fool
    Why Is Seagen Stock Trading Higher Today?
    Via Benzinga
    Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer
    Via Investor's Business Daily
    What's Going On With Neurology Focused Taysha Gene Therapies Stock Today?
    Via Benzinga
    How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin
    Via Investor's Business Daily
    From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
    Via Benzinga
    Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
    Via Talk Markets
    Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles
    Via Benzinga
    The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
    Via Investor's Business Daily
    Why Shares of Annexon Are Plummeting Thursday
    Via The Motley Fool
    Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories
    Via Benzinga
    Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback
    Via Benzinga
    Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
    Via The Motley Fool
    Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
    Via Benzinga
    Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
    Via Investor's Business Daily
    First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
    Via Benzinga
    Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move
    Via Benzinga
    Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
    Via Benzinga
    FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.